Treatment of dyslipidemia in chronic renal failure

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Dyslipidemia in end-stage renal disease is a common problem and may contribute to the high rates of morbidity and mortality in this population. Recent studies indicate that defective lipolysis is a major factor in the development of this disorder which is characterized by increased levels of very-low-density-lipoprotein remnant particles, hypertriglyceridemia and occasionally hypercholesterolemia. There are no prospective longterm studies on the effect of lipid-lowering treatment on morbidity and mortality related to dyslipidemia. Therefore, at present pharmacologic treatment of hyperlipidemia should be undertaken in patients with severe hypertriglyceridemia (> 500 mg/dl) or hypercholesterolemia (LDL > 130 mg/dl) who are at high risk for coronary artery disease. This review discusses the pathogenesis of dyslipidemia, common clinical patterns of hyperlipidemia and various nonpharmacologic and pharmacologic treatment options.

Original languageEnglish (US)
Pages (from-to)75-82
Number of pages8
JournalBlood Purification
Volume14
Issue number1
StatePublished - 1996

Fingerprint

Dyslipidemias
Chronic Kidney Failure
Hypertriglyceridemia
Hypercholesterolemia
Hyperlipidemias
Morbidity
Mortality
VLDL Lipoproteins
Lipolysis
Coronary Artery Disease
Therapeutics
Prospective Studies
Lipids
Population

Keywords

  • Atherosclerosis
  • Cardiovascular complications
  • Dyslipidemia
  • End-stage renal disease
  • Lipid-lowering treatment

ASJC Scopus subject areas

  • Nephrology
  • Hematology

Cite this

Treatment of dyslipidemia in chronic renal failure. / Toto, Robert D.

In: Blood Purification, Vol. 14, No. 1, 1996, p. 75-82.

Research output: Contribution to journalArticle

@article{46ea56ec081e41d78b8183a532397989,
title = "Treatment of dyslipidemia in chronic renal failure",
abstract = "Dyslipidemia in end-stage renal disease is a common problem and may contribute to the high rates of morbidity and mortality in this population. Recent studies indicate that defective lipolysis is a major factor in the development of this disorder which is characterized by increased levels of very-low-density-lipoprotein remnant particles, hypertriglyceridemia and occasionally hypercholesterolemia. There are no prospective longterm studies on the effect of lipid-lowering treatment on morbidity and mortality related to dyslipidemia. Therefore, at present pharmacologic treatment of hyperlipidemia should be undertaken in patients with severe hypertriglyceridemia (> 500 mg/dl) or hypercholesterolemia (LDL > 130 mg/dl) who are at high risk for coronary artery disease. This review discusses the pathogenesis of dyslipidemia, common clinical patterns of hyperlipidemia and various nonpharmacologic and pharmacologic treatment options.",
keywords = "Atherosclerosis, Cardiovascular complications, Dyslipidemia, End-stage renal disease, Lipid-lowering treatment",
author = "Toto, {Robert D.}",
year = "1996",
language = "English (US)",
volume = "14",
pages = "75--82",
journal = "Blood Purification",
issn = "0253-5068",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Treatment of dyslipidemia in chronic renal failure

AU - Toto, Robert D.

PY - 1996

Y1 - 1996

N2 - Dyslipidemia in end-stage renal disease is a common problem and may contribute to the high rates of morbidity and mortality in this population. Recent studies indicate that defective lipolysis is a major factor in the development of this disorder which is characterized by increased levels of very-low-density-lipoprotein remnant particles, hypertriglyceridemia and occasionally hypercholesterolemia. There are no prospective longterm studies on the effect of lipid-lowering treatment on morbidity and mortality related to dyslipidemia. Therefore, at present pharmacologic treatment of hyperlipidemia should be undertaken in patients with severe hypertriglyceridemia (> 500 mg/dl) or hypercholesterolemia (LDL > 130 mg/dl) who are at high risk for coronary artery disease. This review discusses the pathogenesis of dyslipidemia, common clinical patterns of hyperlipidemia and various nonpharmacologic and pharmacologic treatment options.

AB - Dyslipidemia in end-stage renal disease is a common problem and may contribute to the high rates of morbidity and mortality in this population. Recent studies indicate that defective lipolysis is a major factor in the development of this disorder which is characterized by increased levels of very-low-density-lipoprotein remnant particles, hypertriglyceridemia and occasionally hypercholesterolemia. There are no prospective longterm studies on the effect of lipid-lowering treatment on morbidity and mortality related to dyslipidemia. Therefore, at present pharmacologic treatment of hyperlipidemia should be undertaken in patients with severe hypertriglyceridemia (> 500 mg/dl) or hypercholesterolemia (LDL > 130 mg/dl) who are at high risk for coronary artery disease. This review discusses the pathogenesis of dyslipidemia, common clinical patterns of hyperlipidemia and various nonpharmacologic and pharmacologic treatment options.

KW - Atherosclerosis

KW - Cardiovascular complications

KW - Dyslipidemia

KW - End-stage renal disease

KW - Lipid-lowering treatment

UR - http://www.scopus.com/inward/record.url?scp=0030065366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030065366&partnerID=8YFLogxK

M3 - Article

C2 - 8718569

AN - SCOPUS:0030065366

VL - 14

SP - 75

EP - 82

JO - Blood Purification

JF - Blood Purification

SN - 0253-5068

IS - 1

ER -